Please wait while the formulary information is being retrieved.
ONIVYDE (IRINOTECAN LIPOSOMAL)
- Adenocarcinoma of pancreas
4.3 mg/mL intravenous dispersion
- Infuse 70 mg/m2 over 90 minute(s) by intravenous route every 2 weeks
Adenocarcinoma of pancreas
- Infuse 70 mg/m2 over 90 minute(s) by intravenous route every 2 weeks
- Infuse 70 mg/m2 over 90 minute(s) by intravenous route every 14 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- atazanavir
- B cplx-C-St.Johnwrt-K.&S.ginsg
- BCG vaccine, live (PF)
- calcium-mag-B complex-D3-hrb61
- Cold & Flu Fighter
- Fatigue Relief Complex
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- ketoconazole
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Reyataz
- Rotateq Vaccine
- rotavirus vaccine live, penta
- St. John's wort
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- vit C-St. John wort-elder-hb30
- Vivotif Berna Vaccine
- Women's Complex
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- B3,azel,quer&tur-FA-B6-zn-copp
- Belladonna-phenobarbital
- carbamazepine
- Carbatrol
- Cerebyx
- clozapine
- Clozaril
- deferiprone
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Epitol
- Equetro
- Fazaclo
- Ferriprox
- fosphenytoin
- glucosam-csa-mv-min AA-hrb 162
- isoniazid-rifamp-pyrazinamide
- Luminal
- mag oxide-D3-turmeric rt xt
- me-thfolate gluc-B12-herb #236
- milk prot-turm-pepper-pinea ex
- Mycobutin
- Nicazel Forte
- nut.tx, metab.dis, mv & min #4
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Proteolin
- Proteolin Ds
- Rheumate
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- Tegretol
- Tegretol Xr
- Ultra Inflamx Plus 360
- Versacloz
Severe
Moderate
- None
- Acute pancreatitis
- Interstitial pneumonitis
- Lactating mother
- Renal dialysis
Contraindicated
- Anemia
- Bone marrow depression
- Dehydration
- Diarrhea
- Ileus
- Kidney disease with likely reduction in GFR
- Neutropenic disorder
- Pregnancy
- Sepsis
- Thrombocytopenic disorder
- Thromboembolic disorder
- UGt1a1*28 polymorphism
Severe
Moderate
- Chronic pulmonary disease
- Disease of liver
- Hyperbilirubinemia
- Kidney disease with reduction in GFR
ONIVYDE (IRINOTECAN LIPOSOMAL)
- Adenocarcinoma of pancreas
- Anemia
- Diarrhea
- Edema
- Fever
- Leukopenia
- Lymphopenia
- Neutropenic disorder
- Severe bone marrow depression
- Severe diarrhea
- Stomatitis
- Abdominal pain with cramps
- Alopecia
- Anorexia
- Constipation
- Cough
- Dizziness
- Fatigue
- Flushing
- General weakness
- Headache disorder
- Hyperbilirubinemia
- Nausea
- Pain
- Skin rash
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Acute renal failure
- Bacterial sepsis
- Bradycardia
- Gastroenteritis
- Miosis
- Pneumonia
- Abdominal distension
- Back pain
- Chills
- Eye tearing
- Hyperhidrosis
- Intestinal hypermotility
- Rhinitis
- Sialorrhea
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute arterial thromboembolism
- Acute pancreatitis
- Anaphylaxis
- Bacterial infection
- Deep venous thrombosis
- Fungal infection
- Hypersensitivity drug reaction
- Hyponatremia
- Interstitial lung disease
- Myocardial ischemia
- Thrombocytopenic disorder
- Thromboembolic disorder
- Venous thrombosis
- Viral infection
Less Severe
- Dysarthria
- Insomnia
- Periorbital edema
- Pruritus of skin
- Urticaria
Contraindicated
None
Severe Precaution
Irinotecan (Liposomal)
Risk of dehydration, hypokalemia, hyponatremia. No safety and efficacy established.
- 1 Day – 18 Years
- Risk of dehydration, hypokalemia, hyponatremia. No safety and efficacy established.
Management or Monitoring Precaution
None
Irinotecan
- Severity Level:
D
- Additional Notes: Based on drug pharmacology may cause fetal harm
Contraindicated
Irinotecan
Excreted in rat studies;Mfr rec discontinuing breastfeeding during therapy.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Excreted in rat studies;Mfr rec discontinuing breastfeeding during therapy. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Irinotecan liposomal has caused a serious decrease in white blood cells (neutropenia). Low white blood cells can make you more likely to get serious (sometimes fatal) infections or make any infection you have worse. Get medical help right away if you develop signs of infection such as sore throat that doesn't go away, fever, chills.<br /><br /> Your doctor will monitor your blood counts while you are using this medication. Keep all medical and lab appointments. Irinotecan liposomal may cause severe diarrhea which may occur right away and/or more than 24 hours after you receive the medication.<br /><br />If the diarrhea starts right away, you may also have other side effects such as runny nose, increased saliva, watery eyes, sweating, slow heartbeat, stomach cramps, or flushing. You should not receive this medication if you have stomach/intestinal blockage. Tell your doctor right away if you have diarrhea. Your doctor will prescribe medications to help control the diarrhea.
| Adenocarcinoma of pancreas | |
| C24.1 | Malignant neoplasm of ampulla of vater |
| C25 | Malignant neoplasm of pancreas |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.3 | Malignant neoplasm of pancreatic duct |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
| 0-9 | A-Z |
|---|---|
| C24.1 | Malignant neoplasm of ampulla of vater |
| C25 | Malignant neoplasm of pancreas |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.3 | Malignant neoplasm of pancreatic duct |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
Formulary Reference Tool